Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089277 | 0.82 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1LMNAMC4R | |
| SCHEMBL2089705 | 0.82 | SIGMAR1 (0.46) | SIGMAR1ALDH1A1LMNAMC4R | |
| SCHEMBL2089692 | 0.82 | SIGMAR1 (0.46) | SIGMAR1ALDH1A1LMNAMC4R | |
| SCHEMBL4292791 | 0.81 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1LMNAMC4R | |
| SCHEMBL4836946 | 0.81 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1LMNAMC4R | |
| SCHEMBL4842229 | 0.81 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1LMNAMC4R | |
| SCHEMBL7240008 | 0.81 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1LMNAMC4R | |
| Hydrochloric Acid SCHEMBL29257059 | 0.81 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1LMNAMC4R | |
| SCHEMBL13123337 | 0.79 | ALDH1A1 (0.57) | SIGMAR1ALDH1A1FUCA1LMNAMC4R | |
| SCHEMBL27798980 | 0.78 | SIGMAR1 (0.49) | SIGMAR1ALDH1A1LMNAMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | SIGMAR1 367/4885ALDH1A1 1316/4885FUCA1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.